Substituted Heterocyclic Ethers and Their Use in CNS Disorders
申请人:Degnan Andrew P.
公开号:US20090018132A1
公开(公告)日:2009-01-15
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
这项发明涵盖了公式I的化合物,包括药用盐、它们的药物组合物以及它们在治疗中枢神经系统疾病中的用途。
Substituted heterocyclic ethers and their use in CNS disorders
申请人:Bristol-Myers Squibb Company
公开号:US08026257B2
公开(公告)日:2011-09-27
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
The present invention provides a compound or a salt thereof useful for an agent for the prophylaxis or treatment of neurodegenerative disease and the like. The present invention relates to a compound represented by the formula
wherein each symbol is as defined in the present specification, or a salt thereof.
The present invention provides a compound or a salt thereof useful for an agent for the prophylaxis or treatment of neurodegenerative disease and the like. The present invention relates to a compound represented by the formula
wherein each symbol is as defined in the present specification, or a salt thereof.